A Risk-Adapted Strategy of Adjuvant Paclitaxel/Carboplatin in Early-Stage Ovarian Cancer: Time-Dependent Effect of 4 versus 6 Cycles on Outcome

Publisher： Karger

E-ISSN： 1423-0232|81|5-6|365-371

ISSN： 0030-2414

Source： Oncology, Vol.81, Iss.5-6, 2012-01, pp. : 365-371

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Risk-Adapted Therapy in Early-Stage Chronic Lymphocytic Leukemia

By  

Oncology Research and Treatment, Vol. 39, Iss. 1-2, 2016-0 ,pp. : 18-24

Karger

Access to resources Recommend Favorite

Risk-Adapted Chemotherapy in the Adjuvant Setting of Breast Cancer

By  

Oncology Research and Treatment, Vol. 23, Iss. 3, 2000-07 ,pp. : 200-201

Karger

Access to resources Recommend Favorite

Sequential Combination of Paclitaxel-Carboplatin and Paclitaxel-Liposomal Doxorubicin as a First-Line Treatment in Patients with Ovarian Cancer

By  

Oncology, Vol. 69, Iss. 4, 2005-12 ,pp. : 348-353

Karger

Access to resources Recommend Favorite

A 2‐stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early‐stage incident cancers and demonstrates high positive predictive value

By  

CANCER, Vol. 119, Iss. 19, 2013-10 ,pp. : 3454-3461

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long-Term Outcome of Patients with High-Risk Prostate Cancer following Radical Prostatectomy and Stage-Dependent Adjuvant Androgen Deprivation

By  

Urologia Internationalis, Vol. 84, Iss. 2, 2010-03 ,pp. : 164-173

Karger

Access to resources Recommend Favorite